Inhibition of ERK5 activity ameliorates osteoarthritis by suppressing NLRP3 inflammasome-mediated chondrocyte pyroptosis

Abstract

Osteoarthritis (OA) is a widespread degenerative joint disorder manifesting as chronic pain, functional impairment, and progressive disability, imposing a substantial burden on global public health. Despite extensive research, the precise molecular pathways underlying OA pathogenesis remain incompletely elucidated. Our data indicated that human OA cartilage and cartilaginous tissues from aged mice exhibited markedly elevated levels of extracellular signal-related kinase 5 (ERK5) enzyme activity. Using Col2a1-CreER^T2/Erk5^flox/flox mice, we found that Erk5 deletion in cartilage inhibited the progression of post-traumatic and aging OA mouse while constitutive activation of ERK5 significantly accelerated OA development via intra-articular injection of adeno-associated virus model. Mechanistically, ERK5 interacted with the PYD domain of NLRP3 and mediated NLRP3 phosphorylation at serine 198, which facilitated mature inflammasome assembly, triggered pyroptosis and subsequently exacerbated OA progression. Furthermore, we identified a small compound, Oroxylin A, which attenuated ERK5 activation and effectively ameliorated the development of post-traumatic and aging-induced OA in mice. Taken together, our studies demonstrate that ERK5 is a key regulator effecting chondrocytes inflammation and pyroptosis through activating NLRP3 inflammasome and ERK5 is a potential therapeutic target for OA treatment.

References

[1] Global, regional, and national burden of osteoarthritis, 1990-2020 and projections to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Rheumatol. 5, e508–e522 (2023).

[2] Tang S, et al.. Osteoarthritis. Nat. Rev. Dis. Prim., 2025, 11: 10

[3] Barnett R. Osteoarthritis. Lancet, 2018, 391: 1985

[4] Yao Q, et al.. Osteoarthritis: pathogenic signaling pathways and therapeutic targets. Signal Transduct. Target. Ther., 2023, 8: 56

[5] Kolasinski SL, et al.. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the hand, hip, and knee. Arthritis Rheumatol., 2020, 72: 220-233

[6] Sharma L. Osteoarthritis of the Knee. N. Engl. J. Med., 2021, 384: 51-59

[7] Driban JB, et al.. Risk factors and the natural history of accelerated knee osteoarthritis: a narrative review. BMC Musculoskelet. Disord., 2020, 21 332

[8] Motta F, Barone E, Sica A, Selmi C. Inflammaging and osteoarthritis. Clin. Rev. allergy Immunol., 2023, 64: 222-238

[9] Katz JN, Arant KR, Loeser RF. Diagnosis and treatment of hip and knee osteoarthritis: a review. JAMA, 2021, 325: 568-578

[10] Kasler HG, Victoria J, Duramad O, Winoto A. ERK5 is a novel type of mitogen-activated protein kinase containing a transcriptional activation domain. Mol. Cell. Biol., 2000, 20: 8382-8389

[11] Nishimoto S, Nishida E. MAPK signalling: ERK5 versus ERK1/2. EMBO Rep., 2006, 7: 782-786

[12] Nithianandarajah-Jones GN, Wilm B, Goldring CEP, Müller J, Cross MJ. ERK5: structure, regulation and function. Cell. Signal., 2012, 24: 2187-2196

[13] Paudel, R., Fusi, L. & Schmidt, M. The MEK5/ERK5 pathway in health and disease. Int. J. Mol. Sci.22, 7594 (2021).

[14] Rovida E, Navari N, Caligiuri A, Dello Sbarba P, Marra F. ERK5 differentially regulates PDGF-induced proliferation and migration of hepatic stellate cells. J. Hepatol., 2008, 48: 107-115

[15] Simões AES, et al.. Aberrant MEK5/ERK5 signalling contributes to human colon cancer progression via NF-κB activation. Cell Death Dis., 2015, 6: e1718

[16] Sunadome K, et al.. ERK5 regulates muscle cell fusion through Klf transcription factors. Dev. Cell, 2011, 20: 192-205

[17] Wang X, Tournier C. Regulation of cellular functions by the ERK5 signalling pathway. Cell. Signal., 2006, 18: 753-760

[18] Bobick BE, Matsche AI, Chen FH, Tuan RS. The ERK5 and ERK1/2 signaling pathways play opposing regulatory roles during chondrogenesis of adult human bone marrow-derived multipotent progenitor cells. J. Cell Physiol., 2010, 224: 178-186

[19] Iezaki, T. et al. The MAPK Erk5 is necessary for proper skeletogenesis involving a Smurf-Smad-Sox9 molecular axis. Development145, dev164004 (2018).

[20] Wang C, et al.. Sox9-induced chondrogenesis in mesenchymal stem cells was mediated by ERK5 signal pathway. Cell. Mol. Biol., 2016, 62: 1-7

[21] Wilhelmsen K, et al.. Extracellular signal-regulated kinase 5 promotes acute cellular and systemic inflammation. Sci. Signal., 2015, 8: ra86

[22] Finegan KG, et al.. ERK5 is a critical mediator of inflammation-driven cancer. Cancer Res., 2015, 75: 742-753

[23] Seidita I, et al.. Sphingosine 1-phosphate elicits a ROS-mediated proinflammatory response in human endometrial stromal cells via ERK5 activation. FASEB J., 2023, 37 e23061

[24] Ding Y, et al.. Tyrosine phosphatase SHP2 exacerbates psoriasis-like skin inflammation in mice via ERK5-dependent NETosis. MedComm, 2022, 3 e120

[25] Howell SJ, et al.. Retinal inflammation, oxidative stress, and vascular impairment is ablated in diabetic mice receiving XMD8-92 treatment. Front. Pharmacol., 2021, 12 732630

[26] Yang X, et al.. Conditional ablation of MAPK7 expression in chondrocytes impairs endochondral bone formation in limbs and adaptation of chondrocytes to hypoxia. Cell Biosci., 2020, 10: 103

[27] Chen Y, et al.. Targeting TRPA1 with liposome-encapsulated drugs anchored to microspheres for effective osteoarthritis treatment. Chin. Chem. Lett., 2025, 36 110053

[28] Chen X, et al.. Viral glycoprotein-mimicking peptide-functionalized micelles promote drug delivery to diseased chondrocytes for osteoarthritis alleviation. Nat. Nanotechnol., 2026, 21: 300-310

[29] Wang G, et al.. Resveratrol mitigates lipopolysaccharide-mediated acute inflammation in rats by inhibiting the TLR4/NF-κBp65/MAPKs signaling cascade. Sci. Rep., 2017, 7 45006

[30] Katsura H, et al.. Activation of extracellular signal-regulated protein kinases 5 in primary afferent neurons contributes to heat and cold hyperalgesia after inflammation. J. Neurochem., 2007, 102: 1614-1624

[31] Chen Y, et al.. The NLRP3 inflammasome: contributions to inflammation-related diseases. Cell. Mol. Biol. Lett., 2023, 28: 51

[32] Ebata T, et al.. Noncanonical pyroptosis triggered by macrophage-derived extracellular vesicles in chondrocytes leading to cartilage catabolism in osteoarthritis. Arthritis Rheumatol., 2023, 75: 1358-1369

[33] Tang H, et al.. The IRF1/GBP5 axis promotes osteoarthritis progression by activating chondrocyte pyroptosis. J. Orthop. Transl., 2024, 44: 47-59

[34] Gritsenko A, Green JP, Brough D, Lopez-Castejon G. Mechanisms of NLRP3 priming in inflammaging and age related diseases. Cytokine Growth Factor Rev., 2020, 55: 15-25

[35] Mao L, et al.. Bruton tyrosine kinase deficiency augments NLRP3 inflammasome activation and causes IL-1β-mediated colitis. J. Clin., 2020, 130: 1793-1807

[36] Bai H, et al.. Activation of adenosine A3 receptor attenuates progression of osteoarthritis through inhibiting the NLRP3/caspase-1/GSDMD induced signalling. J. Cell. Mol. Med., 2022, 26: 4230-4243

[37] Ma, J. et al. GYY4137-induced p65 sulfhydration protects synovial macrophages against pyroptosis by improving mitochondrial function in osteoarthritis development. J. Adv. Res.71, 173–188 (2024).

[38] Mortimer L, Moreau F, MacDonald JA, Chadee K. NLRP3 inflammasome inhibition is disrupted in a group of auto-inflammatory disease CAPS mutations. Nat. Immunol., 2016, 17: 1176-1186

[39] Swanson KV, Deng M, Ting JP-Y. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nat. Rev. Immunol., 2019, 19: 477-489

[40] Bittner Z. A. et al. BTK operates a phospho-tyrosine switch to regulate NLRP3 inflammasome activity. J. Exp. Med.218, e20201656 (2021).

[41] Ito M, et al.. Bruton’s tyrosine kinase is essential for NLRP3 inflammasome activation and contributes to ischaemic brain injury. Nat. Commun., 2015, 6 7360

[42] Niu T, et al.. NLRP3 phosphorylation in its LRR domain critically regulates inflammasome assembly. Nat. Commun., 2021, 12 5862

[43] Pan H, et al.. Wedelolactone facilitates Ser/Thr phosphorylation of NLRP3 dependent on PKA signalling to block inflammasome activation and pyroptosis. Cell Prolif., 2020, 53 e12868

[44] Qin Y, Zhao W. Posttranslational modifications of NLRP3 and their regulatory roles in inflammasome activation. Eur. J. Immunol., 2023, 53 e2350382

[45] Sandall CF, MacDonald JA. Effects of phosphorylation on the NLRP3 inflammasome. Arch. Biochem. Biophys., 2019, 670: 43-57

[46] Song N, Li T. Regulation of NLRP3 inflammasome by phosphorylation. Front. Immunol., 2018, 9: 2305

[47] Song N, et al.. NLRP3 phosphorylation is an essential priming event for inflammasome activation. Mol. cell, 2017, 68: 185-197.e6

[48] Spalinger MR, et al.. NLRP3 tyrosine phosphorylation is controlled by protein tyrosine phosphatase PTPN22. J. Clin., 2016, 126: 1783-1800

[49] Zhang A, et al.. EphA2 phosphorylates NLRP3 and inhibits inflammasomes in airway epithelial cells. EMBO Rep., 2020, 21 e49666

[50] Zhao W, et al.. AKT regulates NLRP3 inflammasome activation by phosphorylating NLRP3 serine 5. J. Immunol., 2020, 205: 2255-2264

[51] Zhu K, et al.. Priming of NLRP3 inflammasome activation by Msn kinase MINK1 in macrophages. Cell. Mol. Immunol., 2021, 18: 2372-2382

[52] Zhang C, et al.. ADP/P2Y(1) aggravates inflammatory bowel disease through ERK5-mediated NLRP3 inflammasome activation. Mucosal Immunol., 2020, 13: 931-945

[53] Sajeev, A. et al. Oroxylin A: a promising flavonoid for prevention and treatment of chronic diseases. Biomolecules12, 1185 (2022).

[54] Ma Y, et al.. Oroxylin A attenuates psoriasiform skin inflammation by direct targeting p62 (sequestosome 1) via suppressing M1 macrophage polarization. Br. J. Pharmacol., 2024, 181: 5110-5132

[55] Chen D-H, et al.. Oroxylin A attenuates osteoarthritis progression by dual inhibition of cell inflammation and hypertrophy. Food Funct., 2021, 12: 328-339

[56] Zhang, H. et al. Maintaining hypoxia environment of subchondral bone alleviates osteoarthritis progression. Sci. Adv.9, eabo7868 (2023).

[57] Zhang Y, Weng Q, Chen J, Li M, Han J. Oroxylin A attenuates IL-1β-induced inflammatory reaction via inhibiting the activation of the ERK and PI3K/AKT signaling pathways in osteoarthritis chondrocytes. Exp. Ther. Med., 2021, 21: 388

[58] Li Z, et al.. TRIM15 drives chondrocyte senescence and osteoarthritis progression. Sci. Transl. Med., 2025, 17 eadq1735

[59] Liu Q, et al.. SH2 domain-containing phosphatase 2 inhibition attenuates osteoarthritis by maintaining homeostasis of cartilage metabolism via the docking protein 1/uridine phosphorylase 1/uridine cascade. Arthritis Rheumatol., 2022, 74: 462-474

[60] Zhang B, et al.. M13, an anthraquinone compound isolated from Morinda officinalis alleviates the progression of the osteoarthritis via the regulation of STAT3. Phytomed. Int. J. Phytother. Phytopharmacol., 2025, 136156329

[61] Páll S, et al.. Heterogeneous parallelization and acceleration of molecular dynamics simulations in GROMACS. J. Chem. Phys., 2020, 153 134110

[62] van der Spoel D, et al.. GROMACS: fast, flexible, and free. J. Comput. Chem., 2005, 26: 1701-1718

Funding

National Natural Science Foundation of China (National Science Foundation of China)(82572828)

(1)Guangdong Province Basic and Applied Basic Research Fund Project 2023A1515010307 2023B15151200910 (2)Fundamental Research Funds for the Central Universities, Sun Yat-sen University 24qnpy332 (3)Kelin Rising Star Talent Program R08040

Guangzhou Science and Technology Program key projects(2023B0310137)

Rights & permissions

The Author(s)